title: 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
abstract: OBJECTIVE
  To evaluate the role of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the assessment of germ cell tumors after chemotherapy.
  
  
  METHODS
  We reviewed patients' records for the histologic findings and clinical outcome. 18F-FDG PET results were correlated with tissue histologic features where available; and if not available, the correlation was with the clinical outcome.
  
  
  RESULTS
  A total of 45 PET studies were performed on 38 patients (age range 19 to 64 years, median 31). All patients had received chemotherapy. In the nonseminomatous germ cell tumor (NSGCT) group, of the 31 patients with one scan, 18 PET scans were reported as positive, with only 2 not having active disease. Of the 12 negative scans, 6 showed teratoma, 1 tumor, and 5 did not show active disease. The equivocal scan revealed thyroid adenoma. In the seminoma group, the PET scans correlated well with the clinical and histologic outcomes. Four patients underwent salvage chemotherapy, and in this subgroup, the PET findings also correlated with the outcome.
  
  
  CONCLUSIONS
  (18)F-FDG PET is a promising tool as an adjunct to current imaging techniques in detecting residual viable germ cell tumor after chemotherapy. In NSGCT, a positive PET scan was accurate in 16 of 18 patients, although negative PET studies did not exclude the presence of disease, mainly because of the presence of teratoma. In seminoma, a negative 18F-FDG PET study correlated with a favorable clinical outcome. PET was also predictive of the response to salvage chemotherapy and was highly specific for active tumor in both NSGCT and seminoma.
authors.affiliation: Department of Surgery, University of Melbourne, Melbourne, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Johns Putra
authors.forename: L Johns
authors.initials: LJ
authors.lastname: Putra
authors.forename: N
authors.initials: N
authors.lastname: Lawrentschuk
authors.forename: Z
authors.initials: Z
authors.lastname: Ballok
authors.forename: A
authors.initials: A
authors.lastname: Hannah
authors.forename: A
authors.initials: A
authors.lastname: Poon
authors.forename: A
authors.initials: A
authors.lastname: Tauro
authors.forename: I D
authors.initials: ID
authors.lastname: Davis
authors.forename: R J
authors.initials: RJ
authors.lastname: Hicks
authors.forename: D M
authors.initials: DM
authors.lastname: Bolton
authors.forename: A M
authors.initials: AM
authors.lastname: Scott
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D018237:Germinoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D016879:Salvage Therapy; D018239:Seminoma / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18